Search Results

Shanghai Henlius Biotech, Inc. and Organon announced that the European Medicines Agency has validated the marketing authorization applications for HLX14, an investigational Prolia® and Xgeva® biosimilar.

Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. (2696.HK), today announced a strategic collaboration agreement in which Henlius will receive exclusive rights to develop, manufacture and commercialize Sermonix’s lead investigational drug, lasofoxifene, in China.

Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius’ novel anti-PD-1 mAb.

Henlius announced its 2023 annual results. During the reporting period, Henlius’ revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit of RMB546.0 million.

Shanghai Henlius Biotech, Inc. has entered into an exclusive license agreement with PT Kalbe Genexine Biologics, an Indonesian pharmaceutical company and a holding subsidiary to PT Kalbe Farma, Tbk, for the development and commercialisation of HANSIZHUANG as a treatment for two indications including ES-SCLC, Henlius’ novel anti-PD-1 mAb, in 12 Middle East and North African countries including Saudi Arabia, the United Arab Emirates, Egypt, Qatar, Jordan, Morocco, etc.

OncoHost today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases.

HanchorBio Inc. and Shanghai Henlius Biotech, Inc. today announced that the two companies have entered into a strategic framework agreement for collaboration to combine HanchorBio’s protein engineering expertise and proprietary Fc-based designer biologics (FBDB™) technology platform with Henlius’ integrated product development and commercialization capabilities.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.

Henlius（2696.HK）announced its financial results and business update for the first three quarters of 2023.

Shanghai Henlius Biotech, Inc. announced that the new drug application for new indication of HANSIZHUANG in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic ESCC, has been approved by the NMPA, providing a new treatment option for patients with ESCC.